Mendus AB (publ) ROE 2024

Mis teeb Mendus AB (publ)?

Immunicum AB is a biopharmaceutical company based in Stockholm, Sweden. It was founded in 2002 and has been working on developing innovative cancer therapies. The company aims to fight cancer cells in the body by targeting the activation of the body's immune system. Immunicum's business model is based on developing therapies that utilize allogeneic cell therapy. This involves using cells from donors to support specific processes in the body. Immunicum focuses on using dendritic cells as a model to specifically activate the body's immune system and fight cancer cells. The company has various divisions involved in the value chain of cancer therapy. One important area is the research and development of immunotherapies based on allogeneic cell therapy. Dendritic cells in particular are studied and further developed to enhance their effectiveness in fighting cancer. Another important division of Immunicum is clinical development, which involves conducting clinical trials to test and demonstrate the efficacy of the developed therapies in controlled studies. The results can then be used to seek approval for the therapies from regulatory authorities. Commercial development is another crucial area for Immunicum, involving the marketing and sale of the developed therapies. The company works closely with partners in the pharmaceutical industry to distribute the therapies worldwide and make them accessible to patients. Currently, the key product of Immunicum is the medication ilixadencel, which is a therapy based on allogeneic cell therapy that activates dendritic cells. Ilixadencel is being developed and tested as a treatment option for patients with renal cell carcinoma and glioblastoma. The medication is currently in clinical development and has already shown promising results in early studies. In addition to ilixadencel, Immunicum is also working on other products developed based on allogeneic cell therapy. This includes therapies for other types of cancer such as liver cancer and pancreatic cancer. The company has also achieved promising results in this area. Overall, Immunicum is an innovative biotech company aiming to develop new and effective cancer therapies. By specifically activating the body's immune system, their goal is to fight cancer cells and improve the quality of life for patients. The company has already made promising developments in this field and continues to work on improving the effectiveness of its therapies. Mendus AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.